CapsoVision, Inc. (CV) AI Stock Analysis

CapsoVision, Inc. manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. Its product portfolio includes CapsoCam Plus for visualizing small bowel mucosa in adults and children aged 2 and older, CapsoCam Colon for colon visualization and polyp detection, and CapsoColon 3D in development for the large intestine. The company also provides the CapsoCloud cloud-based software-as-a-service ecosystem for video access, CapsoView data access reading devices, CapsoAccess data systems, CapsoRetrieve magnetic retrieval kits, and capsule video reading services. It sells primarily to distributor customers who resell to gastrointestinal practices, clinics, and hospitals.

Annual revenue increased from $9.8M in FY2023 to $11.8M in FY2024 and reached $13.6M in FY2025, reflecting a 17.9% two-year compound annual growth rate. Gross margin contracted across that period, moving from 56.3% in FY2023 to 54.2% in FY2024 and 52.9% in FY2025. Operating losses widened as research and development expenses increased from $9.3M in FY2023 to $18.3M in FY2025, leading to an operating margin of -188.3% and net income of -$25.3M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $13.9M with an operating margin of -208.1% and diluted EPS of -$0.45, while latest quarterly revenue grew 9.9% year-over-year.

As of June 30, 2026, CapsoVision held $9.1M in cash and short-term investments and $687,000 in total debt, resulting in net cash of $8.4M. Shareholders' equity was $13.2M against total assets of $18.6M, yielding a current ratio of 3.35 and a debt-to-equity ratio of 0.05. In FY2025, the company used $22.9M in operating cash flow and recorded -$23.0M in free cash flow, while capital expenditures totaled $90,000.

At a share price of $6.53, CapsoVision has a market capitalization of $347.5M and an enterprise value of $313.5M. The stock trades at a price-to-sales multiple of 25.0x and an EV-to-revenue ratio of 22.6x, compared to the median of 4.1x price-to-sales for its US-listed Healthcare peers. Over the trailing 12 months, the stock gained 41.6%, outperforming the 16.8% return of the S&P 500 (SPY), though it is down 38.9% year-to-date.

Wall Street coverage includes 2 Strong Buy ratings with no Hold or Sell recommendations. The mean price target is $9.50, representing a 45.5% premium to the last closing price of $6.53. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $14.9M and EPS of -$0.56. For FY2027, 2 analysts forecast revenue of $19.8M, representing 33.3% growth, with EPS of -$0.44. Over the last 4 quarters, the company recorded 0 EPS beats, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of CapsoVision, Inc. (CV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CV income statement, CV balance sheet, CV key metrics, CV analyst forecast, CV chart. See the CV stock overview for the latest quote and news.